Ignite Creation Date:
2025-12-24 @ 3:24 PM
Ignite Modification Date:
2026-03-01 @ 10:04 AM
Study NCT ID:
NCT03347292
Status:
COMPLETED
Last Update Posted:
2023-07-25
First Post:
2017-11-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-18
Start Date Type:
ACTUAL
Primary Completion Date:
2020-12-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-06
Completion Date Type:
ACTUAL
First Submit Date:
2017-11-16
First Submit QC Date:
None
Study First Post Date:
2017-11-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-07-24
Last Update Post Date:
2023-07-25
Last Update Post Date Type:
ACTUAL